Aldara Approved for Superficial Basal Cell Carcinoma

"3M Co. said on Thursday the U.S. Food and Drug Administration has approved its Aldara (imiquimod) drug as a treatment for superficial basal cell carcinoma. The company had received approval in March to market Aldara for actinic keratosis."